Synthesis and Pharmacological Characterization of Novel Druglike Corticotropin-Releasing Factor 1 Antagonists
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
To identify new CRF(1) receptor antagonists, an attempt to modify the bis-heterocycle moiety present in the top region of the dihydropyrrole[2,3]pyridine template was made following new pharmacophoric hypothesis on the CRF(1) receptor antagonists binding pocket. In particular, the 2-thiazole ring, present in the previous series of compounds, was replaced by more hydrophilic non aromatic heterocycles able to make appropriate H-bond interactions with amino acid residues Thr192 and Tyr195. This exploration, followed by an accurate analysis of the substitution of the pendant aryl ring, enabled to identify in vitro potent compounds showing excellent pharmacokinetics and outstanding in vivo activity in animal models of anxiety, both in rodents and primates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“using oral administration of the selective CRF-R1 antagonist GSK876008 (Di Fabio et al, 2008), at doses that dose dependently (linear) disrupt CRF-enhanced startle, we also observed a non-monotonic disruption of light-enhanced startle but no disruption of fear-potentiated startle in the same animals at the same doses”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as Di Fabio et al, 2008
Citations
Cites
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981) · Science · doi:10.1126/science.6267699 · Cited by 3,965
VALE, W., SPIESS, J., RIVIER, C., & RIVIER, J. (1982) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198205000-00013 · Cited by 3,904
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Holsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Rivier, C., & Vale, W. (1983) · Nature · doi:10.1038/305325a0 · Cited by 539
Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S., Webster, E. L., Atkinson, A. J., Schulkin, J., Contoreggi, C., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6079 · Cited by 403
De Souza, E. B. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00011-9 · Cited by 395
Schulz, D. W., Mansbach, R. S., Sprouse, J., Braselton, J. P., Collins, J., Corman, M., Dunaiskis, A., Faraci, S., Schmidt, A. W., Seeger, T., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10477 · Cited by 377
Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist
Mansbach, R. S., Brooks, E. N., & Chen, Y. L. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00025-3 · Cited by 195
Distress vocalization in rat pups a simple screening method for anxiolytic drugs
Gardner, C. R. (1985) · Journal of Pharmacological Methods · doi:10.1016/0160-5402(85)90031-2 · Cited by 181
Research works printed but not linked: 3
- Owen M. J., 1991, Pharmacol. Res., 43, 425
- Di Fabio R., 2008, J. Med. Chem.
- Arunlakshana O., 1959, Br. J. Pharmacol., 14, 48
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
“However, using oral administration of the selective CRF-R1 antagonist GSK876008 (Di Fabio et al, 2008), at doses that dose dependently (linear) disrupt CRFenhanced startle, we also observed a non-monotonic disruption of light-enhanced startle but no disruption of fear-potentiated startle in the…”
Walker, D. L., Miles, L. A., & Davis, M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.022 · Cited by 331
“…potency (pA2) of 7.14 ± 0.12 on recombinant human CRF1 receptors expressed in CHO cells, but is inactive on human CRF2 receptors or the CRF binding protein, or on 83 other G-protein coupled receptors, channels, enzymes and transporters up to a concentration of 10 µM (di Fabio et al., 2008).”
BackgroundInfluentialProgress in corticotropin-releasing factor-1 antagonist development
Zorrilla, E. P., & Koob, G. F. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.02.011 · Cited by 167
“7), including the clinical candidate GW876008 (see below) [95].”
BackgroundZorrilla, E. P., Heilig, M., de Wit, H., & Shaham, Y. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.017 · Cited by 108
Kokras, N., Hodes, G. E., Bangasser, D. A., & Dalla, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14710 · Cited by 100
“Another CRF1 antagonist, verucerfont, lacked efficacy in a clinical trial of 150 depressed women, and no men (NCT00733980), despite the fact that the original behavioural testing was done in male animals (Fabio et al., 2008).”
Background
Metadata
- Authors
- Fabio, R. D., St-Denis, Y., Sabbatini, F. M., Andreotti, D., Arban, R., Bernasconi, G., Braggio, S., Blaney, F. E., Capelli, A. M., Castiglioni, E., Modugno, E. D., Donati, D., Fazzolari, E., Ratti, E., Feriani, A., Contini, S., Gentile, G., Ghirlanda, D., Provera, S., Marchioro, C., Roberts, K. L., Mingardi, A., Mattioli, M., Nalin, A., Pavone, F., Spada, S., Trist, D. G., & Worby, A.
- Affiliations
- GlaxoSmithKline (Italy) (IT)
- Neurosciences Centre of Excellence for Drug Discovery and Molecular Discovery Research, GlaxoSmithKline Medicines Research Centre, Via A. Fleming 4, 37135, Verona, Italy, Molecular Discovery Research, GlaxoSmithKline NFSP, Harlow, United Kingdom, GlaxoSmithKline Medicines Research Centre, Global Project Management, Via A. Fleming 4, 37135, Verona, Italy
- Corresponding author
- Fabio, Romano Di
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-11-07
- Volume
- 51
- Issue
- 23
- Pages
- 7370-7379
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1969850793
- Cited by
- 34
- References
- 19
- Citations by year
- 2020: 2 · 2019: 1 · 2017: 4 · 2016: 2 · 2015: 1 · 2014: 6 · 2013: 4 · 2012: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Neurocrine Biosciences
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- CRF1 receptor antagonist, pharmacophore hypothesis, pharmacokinetics, anxiety models, nonhuman primate model
- MeSH terms
- CRF Receptor, Type 1, Animals, Dose-Response Relationship, Drug, Exploratory Behavior, Female, Forelimb, Gerbillinae, Humans, Male, Models, Chemical, Motor Activity, Psychological Tests, Pyridines, Pyrroles, Stereoisomerism, Ultrasonics, Vocalization, Animal, Molecular Structure, Rats, Sprague-Dawley, Receptors, Corticotropin-Releasing Hormone, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.